
My commentary on the LTFU data from Short et al in Blood Advances with the addition of Gilteritinib to Azacitidine and Venetoclax for FLT3 mutant AML. Encouraging OS(29.7m) but myelosuppression in older adult(71 YO median) population remains a challenge. ashpublications.org/bloodadv…





































